Efficacy of a Vibrating Facial-T- Massager as an Adjunct to Topical Anesthesia in Reducing Intraoral Injection Pain in Children: A Randomized Controlled Trial.

Abstract
* Background: Local anesthesia is a primary source of anxiety in pediatric dentistry.
* Objective: To evaluate if mechanical vibration from a low-cost facial massager reduces pain and anxiety during injections using the Gate Control Theory.
* Design: Prospective Randomized Controlled Trial .

Start Date01 Jun 2026

Sponsor / Collaborator-

CTRI/2026/03/105561

/ RecruitingNot ApplicableIIT

Comparative evaluation of pain perception on topical application of 20 percent benzocaine gel and a vibratory stimulus during local anesthesia administration in pediatric patients: a randomised controlled trial - NIL

Start Date28 Apr 2026

Sponsor / Collaborator-

IRCT20260217068902N1

/ CompletedNot ApplicableIIT

Comparison of the Efficacy of 20% Benzocaine and 20%Lidocaine Gels in Reducing Pain of Local Anesthetic Injectionin Dental Procedures

Start Date06 Mar 2026

Sponsor / Collaborator-

100 Clinical Results associated with Ethyl Aminobenzoate

100 Translational Medicine associated with Ethyl Aminobenzoate

100 Patents (Medical) associated with Ethyl Aminobenzoate

4,519

Literatures (Medical) associated with Ethyl Aminobenzoate

01 Nov 2026·ARCHIVES OF GERONTOLOGY AND GERIATRICS

Microglial PICALM: A novel genetic driver and therapeutic target in vascular dementia

Article

Author: Cheng, Dan ; Yang, Jiqi ; Chai, Zhaohui ; Liu, Zongchi ; Gong, Jiangbiao ; Zhang, Yuning ; Gu, Jun ; Wang, Liyun ; Xu, Qiuhan ; Shen, Jian ; Liu, Wenchao ; Li, Hongyu ; Zhu, Yu ; Zheng, Jiesheng

BACKGROUND:

Vascular dementia (VaD) lacks well-defined genetic mechanisms. Cell-type-specific effects of GWAS loci remain unexplored.

METHODS:

We integrated single‑cell eQTL data (183 donors, eight cell types) with VaD GWAS (3624 cases, 475,484 controls) using Mendelian randomization and Bayesian colocalization, replicated in an independent cohort (2074 cases, 456,366 controls). Subtype, snRNA‑seq, cell‑cell communication, PheWAS, expression profiling, and drug prediction with BBB permeability assessment were performed.

RESULTS:

Microglial PICALM was the only robustly replicated signal (OR = 0.8334, p = 5.3 × 10⁻⁴; colocalization PP.H4 > 0.75). The effect was strongest in multiple infarctions dementia (OR = 0.7746). Exploratory snRNA-seq analysis (4 VaD vs. 4 controls; GSE282111) provided supporting evidence for microglial PICALM enrichment and downregulation (p < 0.001). PICALM‑high microglia showed enhanced neurovascular‑ and phagocytosis‑related communication (e.g., SPP1, GAS6, GRN). PheWAS revealed no pleiotropy. In silico drug repurposing prioritised three FDA-approved BBB-penetrant compounds (disopyramide, benzocaine, amantadine) as candidates warranting further mechanistic validation.

CONCLUSIONS:

Microglial PICALM is identified as a likely genetic determinant of VaD, especially in the multiple infarctions subtype. Upregulating PICALM may be associated with a neuroprotective microglial phenotype, highlighting PICALM as a candidate therapeutic target warranting further experimental validation.

01 Oct 2026·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Development of dissolving polymeric microneedles loaded with benzocaine nanocrystals as an effective intradermal drug delivery system

Article

Author: Abbas, Ayman Alhaj ; Jabaiti, Omar ; Abdelghany, Sharif

The development of dissolving polymeric microneedles (DPMNs) loaded with drug nanocrystals is an innovative and minimally invasive approach for localized drug administration. In this work, benzocaine, a short-acting local anesthetic, was formulated into nanocrystals (BZ-NCs) and subsequently incorporated into polymeric microneedles. Several formulations of BZ-NCs were formulated via nanoprecipitation technique, utilizing ethanol as a solvent and varying aqueous concentrations of sodium lauryl sulfate (SLS), Polysorbate 80, or Poloxamer 188 as the antisolvent. The optimized formulation of BZ-NCs, which was developed utilizing 0.5% w/v SLS in the antisolvent phase, was assessed employing attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR), powder X-ray diffraction (PXRD), and differential scanning calorimetry (DSC). Moreover, the dissolution behavior of BZ-NCs was compared to that of plain benzocaine (BZ). DPMNs loaded with the optimized BZ-NCs formulation were prepared by mixing 25% w/w polyvinyl alcohol (PVA) and 35% w/w polyvinyl pyrrolidone (PVP) at ratios of 1:3, 1:2, or 1:1, respectively. The favorable formulation (1:1) was selected for further evaluation, including dissolution, accelerated stability, histological assessment and dermatokinetic analysis. The optimized nanocrystal formulation (BZ-NCs-3), exhibited a particle size of 291.12 ± 15.31 nm with polydispersity index and zeta potential of 0.261 ± 0.090 and -32.27 ± 1.04, respectively. ATR-FTIR confirmed the chemical structure integrity of benzocaine in BZ-NCs-3, while PXRD and DSC revealed its crystalline nature. Moreover, the dissolution of BZ-NCs-3 was significantly enhanced at pH 5.5 and 7.4 compared to BZ. The optimal microneedle formulation (BZNCs-MN3), having the highest PVA content, demonstrated effective penetration in excised human skin reaching a depth of 394.19 ± 20.402 µm, dissolved within 25 min and showed no significant changes in benzocaine content after accelerated storage. According to the dermatokinetic analysis, delayed and superior deposition of benzocaine in the epidermis and dermis were recorded following the application of BZNCs-MN3. This platform provides promise for improving local anesthesia with higher distribution of benzocaine in skin layers.

01 Oct 2026·Clinical and Experimental Dental Research

Topical Anesthetics Effectiveness in Management of Orthodontic Pain: A Systematic Review of Randomized Controlled Trials

Review

Author: Jehangir, Adnan ; Naseem, Waqas ; Altuhafy, Maryam ; Naseem, Abbas ; Khan, Junad ; Khalid, Qasim ; Hussain, Umar

ABSTRACT:

Objectives:

Orthodontic treatment can be associated with pain, particularly during separator placement, appliance insertion, or activation. Topical anesthetics may offer a simple, locally applied alternative to systemic analgesics, but their effectiveness remains uncertain. The objective of this review was to evaluate the efficacy of topical anesthetics, compared to other treatments or no treatment, in reducing orthodontic pain.

Material and Methods:

Eligible studies were randomized controlled trials (RCTs) comparing topical anesthetics (gels or patches) with placebo, no treatment, or other active pain‐control interventions in orthodontic patients. Five databases (PubMed, Scopus, Cochrane CENTRAL, Embase, Web of Science) were searched up to 14th March 2026, with no language or date restrictions. Data were extracted in duplicate, and the risk of bias was assessed using the ROB‐2 tool. Due to heterogeneity, only a qualitative synthesis was performed.

Results:

Nine RCTs (456 participants, mean age 14–35 years; 36.3% male) conducted in four countries were included. Benzocaine was the most investigated, followed by lidocaine, prilocaine/lidocaine, and menthol. Most studies examined separator‐induced pain. Eight of nine trials reported significant reductions in pain intensity with topical anesthetics at one or more time points, particularly within the first 24 to 72 h. Benzocaine consistently showed superior outcomes compared with placebo. Lidocaine and prilocaine/lidocaine provided rapid analgesia, especially in patients with high anxiety or low pain thresholds. Menthol patches also showed significant short‐term pain reduction in two studies. Risk of bias was moderate in most trials.

Conclusion:

Topical anesthetics can be effective in reducing short‐term orthodontic pain. Their use may reduce reliance on systemic analgesics and improve patient comfort during the initial stages of treatment. However, evidence quality remains limited, and further high‐quality RCTs with standardized protocols are needed.

News (Medical) associated with Ethyl Aminobenzoate

19 Aug 2026

·www.prnewswire.com

Arcato Announces Phase 1 Clinical Trial Results and Closing of Fully Subscribed Financing Round

--ARC-001 Gel demonstrates safety following third molar surgery-- --Exploratory analyses suggest durable analgesia as single dose ARC-001 Gel reduces post-operative pain within the first 24 hours and potentially for up to 1 week-- GREENVILLE, N.C., Aug. 19, 2026 /PRNewswire/ -- Arcato Laboratories, Inc. () today simultaneously announced successful topline results from its first-in-human Phase 1 study of ARC-001 Gel in patients following third molar (wisdom tooth) extraction surgery, as well as the closing of its first round of financing. ARC-001 Gel is a novel, proprietary, sustained release single-dose gel formulation combining 3 well characterized, non-addictive anesthetics: Benzocaine, Lidocaine, and Bupivacaine. The novel formulation of ARC-001 Gel allows for a one-time local administration into the tooth socket following surgical extraction, with a pharmacokinetic profile supporting the potential for pain relief for up to 7 days. ARC-001 Gel does not require an injection or a needle; the gel is easily administered directly into the extraction socket. The Phase 1 primary endpoint of safety was achieved, supporting further Phase 2/3 development. Exploratory efficacy endpoints suggest pain reduction within the first 24 hours and that a single dose of ARC-001 Gel may provide pain relief for up to one week. Further exploratory analyses demonstrated that patients on placebo self-reported a need for opioids twice as often as those on ARC-001 Gel to manage pain. "The dental and oral surgery community welcome the work Arcato is doing to develop a pain treatment specifically for oral health. ARC-001 Gel is a unique approach to local pain management after third molar surgery, combining three well known anesthetics in a novel formulation. With more than 3 million patients per year in the US having third molar surgery, new pain management options are needed. While progress has been made in reducing post-operative opioid use, there is much work to be done," said Dr. Thomas E. Van Dyke, DDS, PhD, Vice President of Clinical and Translational Research at the ADA Forsyth Institute. "Our clinical results demonstrate that ARC-001 Gel is an exciting new approach to managing oral pain. We are actively engaged with the FDA, closely aligned with their May 2026 draft development guidance for non-opioid analgesics. Moreover, I would like to thank the Arcato team, as well as our investors, at this exciting milestone," said Jeff Miller, Chief Executive Officer of Arcato Laboratories. SOURCE Arcato 21% more press release views with Request a Demo

Phase 1Clinical Result

10 Mar 2025

·www.pharmaceutical-technology.com

Alliance Pharma agrees to £362m acquisition by DBAY

DBAY advisors initially approached Alliance Pharma in 2024. Credit: DjelicS via Getty Images. UK-based Alliance Pharma has agreed to a final increased cash offer from asset management company DBAY Advisors, valuing the former at approximately £362m ($467.5m). The offer, made through a newly formed company called Aegres Bidco Limited, will see DBAY acquire all shares in Alliance, except those it already owns through its affiliates, for 64.75p per share. This represents a 3.6% increase from DBAY’s initial offer of 62.5p per share in January 2025 and a 46% premium on Alliance’s share price as of 9 January 2025, the day before the offer period began. Alliance Pharma specialises in the marketing and distribution of consumer healthcare products and prescription medicines. Its portfolio includes Kelo-Cote, a scar treatment; and Anbesol (benzocaine), an oral pain relief product. DBAY initially approached Alliance last year, following a series of challenges faced by the company, including the delayed publication of its annual results and the resignation of its CEO Peter Butterfield. Having gradually increased its stake in the company over two years, DBAY now holds a 27.9% share of Alliance. In its initial takeover offer, DBAY stated that it believed Alliance had “strong future prospects” but required significant operational changes and increased investment to maximise its growth potential. The asset management company argued that such changes would be more effectively implemented away from the pressures of the public market. In January 2025, Alliance’s board of directors recommended shareholders accept the initial offer of 62.5p per share. However, after receiving feedback from shareholders, the scheduled general meeting last month was adjourned to allow for further discussions. According to a 10 March filing on the London Stock Exchange, DBAY will fund the acquisition through a combination of equity investments from its affiliated funds and external financing, with a small portion of shares in Midco, the parent company of Bidco, being offered to certain lenders. Shareholders are expected to vote on the proposal at a rescheduled meeting on 13 March 2025. If approved, the deal is anticipated to be completed in the first half of 2025, resulting in Alliance Pharma becoming a privately owned company under DBAY’s control. In September 2024, Alliance reported underlying revenue of £84m for the six months to 30 June 2024, reflecting an increase from £81.4m in the same period the previous year. Profit before tax also rose year-on-year, reaching £12.7m compared to £10.3m in 2023.

AcquisitionFinancial StatementExecutive Change

23 Aug 2024

·pharma.economictimes.indiatimes.com

Govt bans 156 medicines including antibiotics, painkillers, multivitamins: Here is the full list

New Delhi: In a significant move aimed at safeguarding public health, the Indian government has banned 156 fixed-dose combination (FDC) drugs, including a variety of antibiotics, painkillers, multivitamins, and medications for treating fever and hypertension. This decision marks the largest crackdown on FDCs since 2016, when 344 such drugs were prohibited. The Union Ministry of Health and Family Welfare issued a gazette notification on Thursday, officially prohibiting the manufacture, sale, and distribution of the banned FDCs. The ban was based on the recommendations of an expert panel that reviewed a total of 324 FDCs. Impact on Pharmaceutical Industry The banned FDCs include popular combinations such as mefenamic acid and paracetamol injections, commonly used for pain relief and fever, and omeprazole magnesium with dicyclomine HCl, used to treat abdominal pain. The ban is expected to impact major pharmaceutical companies, including Sun Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories. Fixed Dose Combinations Drug Banned List Here is a table listing all 156 banned Fixed Dose Combinations (FDCs) SN Fixed Dose Combination (FDC) 1 Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain 2 Antimony Potassium Tartrate + Dried Ferrous Sulphate 3 Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride 4 Bismuth Ammonium Citrate + Papain 5 Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide 6 Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride 7 Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide 8 Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol 9 Mefenamic Acid + Paracetamol Injection 10 Omeprazole Magnesium + Dicyclomine HCl 11 S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L- Methylfolate + Choline bitartratee + Silymarin + L-ornithine Laspartate + Inositol + Taurine 12 Silymarin + Thiamine Mononitrate + Riboflavin + Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12 13 Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid 14 Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate 15 Sodium Citrate + Citric Acid Monohydrate Flavored with Cardamom Oil, Caraway Oil, Cinnamon Oil, Clove Oil, Ginger Oil + Alcohol 16 Sucralfate + Acelofenac 17 Sucralfate + Domperidone + Dimethicone 18 Sucralfate + Domperidone 19 Tincture Ipecacuanha + Tincture Urgenia + Camphorated Opium Tincture + Aromatic Spirit of Ammonia + Chloroform + Alcohol 20 Ursodeoxycholic Acid + Metformin HCl 21 Weak Ginger tincture + Aromatic Spirit of Ammonia + Peppermint Spirit + Chloroform + Sodium Bicarbonate + Compound Cardamom + Alcohol 22 Sucralfate + Pantoprazole Sodium + Zinc Gluconate + Light Magnesium Carbonate 23 Aloe + Vitamin E Soap 24 Povidone Iodine+ Metronidazole + Aloe 25 Azelaic acid + Tea Tree Oil + Salicylic acid + Allantoin + Zinc oxide + Aloe vera + Jojoba oil + Vitamin E + Soap noodles 26 Azithromycin + Adapalene 27 Calamine + Aloes + Allantoin 28 Calamine + Diphenhydramine Hydrochloride + Aloe + Glycerine + Camphor 29 Chlorphenesin + Zinc oxide + Starch 30 Clindamycin Phosphate + Zinc acetate 31 Gamma Benzene Hexachloride + Benzocaine 32 Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin 33 Hydroxyquinone 2.0%w/w + Octyl Methoxycinnamate 5.0% w/w + Oxybenzone 30 % w/w 34 Ketoconazole +Zinc Pyrithione +D-Panthenol +Tea Tree Oil +Aloes 35 Ketoconazole +Aloe vera+ Vitamin A Acetate 36 Ketoconazole +Aloes + ZPTO 37 Kojic Acid +Arbutin +Octinoxate +Vitamin E + Mulberry 38 Lornoxicam +capsaicin +menthol+ camphor 39 Lornoxicam + Thiocolchicoside +Oleum Lini +Menthol + Methyl salicylate 40 Menthol + Aloe vera Topical Spray 41 Menthol +Lignocaine HCl +Aloe vera gel +Clotrimazole +Diphenhydramine 42 Miconazole nitrate + Gentamicin + Fluocinolone Acetonide +Zinc Sulphate 43 Miconazole +Tinidazole 44 Minoxidil +Aminexil+ Alcohol 45 Minoxidil +Azelaic acid + saw palmetto 46 Minoxidil +Aminexil 47 Pine Bark extract+ Kojic acid +Sodium Ascorbyl Phosphate 48 Povidone Iodine +Tinidazole +Zinc sulphate 49 Povidone Iodine + Ornidazole + Dexpanthenol 50 Salicyclic acid +Aloe vera+ Allantoin +D-Panthenol 51 Silver sulphadiazine +Chlorhexidine Gluconate solution +Allantoin + Aloe vera gel +Vitamin E acetate 52 Sodium salicylate + Zinc gluconate + Pyridoxine HCl 53 Tetracycline + Colistin Sulphate 54 Clomiphene +Ubidecarenone 55 Combikit of Clomiphene Citrate + Estradiol Valerate 56 Flavoxate HCl +Ofloxacin 57 Clomiphene Citrate +N-Acetylcysteine 58 Primerose Oil +Cod liver oil 59 Sildenafil Citrate +Papaverine +L-Arginine 60 Tranexamic acid +Mefenamic acid + Vitamin K1 61 Divalproex Sodium +Oxcarbazepine 62 Divalproex Sodium + Levetiracitam 63 Ergotamine tartrate +Caffeine + Paracetamol +Prochlorperazine maleate 64 Piracetam + Ginkgo biloba extracts + Vinpocetin 65 Ginkgo biloba + methylcobalamin 66 Ginkgo biloba + methylcobalamin + Alpha lipoic acid +Pyridoxine HCl 67 Ginseng Extract +Dried extract of Ginkgo Biloba 68 Meclizine HCl+ Paracetamol + Caffeine 69 Nicergoline + Vinpocetine 70 Gamma Linolenic Acid + Methylcobalamin 71 Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl 72 Boric acid+ Phenylephrine HCl + Naphazoline Nitrate + Menthol + Camphor 73 Naphazoline HCl + Chlorpheniramine Maleate + Zinc Sulphate + Hydroxy Propyl Methyl Cellulose 74 Chlorpheniramine Maleate + Naphazoline HCl + Zinc Sulphate + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 75 Chlorpheniramine Maleate + Naphazoline HCl + Hydroxy Propyl Methyl Cellulose 76 Chlorpheniramine Maleate + Sodium Chloride + Boric Acid + Tetrahydrozoline HCl 77 Chlorpheniramine Maleate + Phenylephrine HCl + Antipyrine 78 Ketorolac Tromethamine + Chlorpheniramine Maleate + Phenylephrine HCl + Hydroxy Propyl Methyl Cellulose 79 Ketorolac Tromethamine + Flurometholone 80 Naphazoline HCl + Zinc Sulphate + Boric Acid + Sodium Chloride+ Chlorpheniramine Maleate 81 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Boric Acid + Borax + Menthol + Camphor 82 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Chlorpheniramine Maleate SN Fixed Dose Combination (FDC) 83 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Menthol + Camphor 84 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 85 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Methylparaben 86 Methenamine + Sodium Benzoate + Benzyl Alcohol 87 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 88 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate + Caffeine 89 Propoxyphene + Chlorpheniramine Maleate 90 Propoxyphene + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 91 Propoxyphene + Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride 92 Sodium Benzoate + Sodium Citrate + Citric Acid 93 Vitamin A Palmitate + Vitamin C + Vitamin E + Vitamin B6 + Vitamin B12 94 Vitamin A Palmitate + Vitamin C + Vitamin E + Niacinamide 95 Vitamin B6 + Vitamin B12 + Vitamin C 96 Vitamin B6 + Vitamin B12 + Niacinamide 97 Vitamin B12 + Vitamin B6 + Vitamin C + Folic Acid 98 Vitamin B12 + Vitamin B6 + Niacinamide + Folic Acid 99 Vitamin C + Vitamin E + Vitamin A + Niacinamide 100 Vitamin D + Calcium + Magnesium 101 Vitamin D + Calcium + Magnesium + Zinc 102 Calcium + Vitamin D + Vitamin K 103 Calcium + Vitamin D + Magnesium + Zinc 104 Calcium + Vitamin D + Vitamin K + Magnesium 105 Calcium + Vitamin D + Vitamin K + Magnesium + Zinc 106 Vitamin E + Vitamin A + Vitamin C + Niacinamide 107 Vitamin E + Vitamin A + Vitamin C + Folic Acid 108 Vitamin E + Vitamin A + Vitamin C + Biotin 109 Vitamin E + Vitamin A + Vitamin C + Vitamin B12 110 Vitamin E + Vitamin C + Folic Acid 111 Vitamin E + Vitamin C + Biotin 112 Vitamin E + Vitamin C + Vitamin B12 113 Vitamin E + Vitamin C + Zinc 114 Calcium + Vitamin D + Omega-3 Fatty Acids 115 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K 116 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Magnesium 117 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Zinc 118 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene 119 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene + Zinc 120 Vitamin C + Vitamin E + Beta-Carotene 121 Vitamin C + Vitamin E + Beta-Carotene + Zinc 122 Vitamin C + Vitamin E + Selenium 123 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids 124 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Magnesium 125 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Zinc 126 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Biotin 127 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 128 Vitamin E + Vitamin A + Vitamin C + Zinc 129 Vitamin E + Vitamin A + Vitamin C + Selenium 130 Vitamin E + Vitamin A + Vitamin C + Biotin 131 Vitamin E + Vitamin A + Vitamin C + Folic Acid + Niacinamide 132 Vitamin E + Vitamin C + Beta-Carotene + Zinc 133 Vitamin C + Vitamin E + Biotin + Folic Acid 134 Vitamin C + Vitamin E + Beta-Carotene + Folic Acid 135 Vitamin C + Vitamin E + Beta-Carotene + Selenium 136 Vitamin E + Vitamin C + Beta-Carotene + Biotin 137 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Biotin 138 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 139 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B12 140 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B6 141 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Folate 142 Calcium + Vitamin D + Magnesium + Vitamin K + Omega-3 Fatty Acids 143 Calcium + Vitamin D + Magnesium + Vitamin K + Biotin 144 Calcium + Vitamin D + Magnesium + Vitamin K + Selenium 145 Calcium + Vitamin D + Magnesium + Vitamin K + Vitamin B12 146 Calcium + Vitamin D + Magnesium + Vitamin K + Folate 147 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B6 148 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B12 149 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Folic Acid 150 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Biotin 151 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Selenium 152 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids 153 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Zinc 154 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Biotin 155 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Selenium 156 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Vitamin B12

Drug Approval

100 Deals associated with Ethyl Aminobenzoate

External Link

KEGG	Wiki	ATC	Drug Bank
D00552	Ethyl Aminobenzoate	D04AB04 R02AD01 N01BA05	DB01086

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	Japan	Agsa Japan Co., Ltd.	11 May 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent aphthous ulcer	Phase 3	China	Shanghai Institute of Pharmaceutical Industry	13 Aug 2014
Acute otitis media	Phase 3	United States	Arbor Pharmaceuticals, Inc.	01 Dec 2013
Pain	Phase 3	United States	Arbor Pharmaceuticals, Inc.	01 Dec 2013
Earache	Phase 2	United States	Arbor Pharmaceuticals, Inc.	01 May 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06011005 (Pubmed \| Front Dent Med)	Not Applicable	Pain	57	20% Benzocaine Gel	hujftmlcgt(ivdlhjbgyx) = lppnjwiuri jqpkicpsxk (xzwkoamkor ) View more	Negative	19 Aug 2026
				Ethyl Chloride Spray	hujftmlcgt(ivdlhjbgyx) = fewuegfwvt jqpkicpsxk (xzwkoamkor ) View more
NCT06272903 (Pubmed \| Int J Clin Pediatr Dent)	Phase 1	Pain, Procedural	32	Benzocaine 20% topical anesthesia gel (BZG)	certkxajpz(zxxdrmtcdm): P-Value = 0.045 View more	Positive	02 Mar 2026
				Placebo
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group)	leostgbycj = ujtuhctbzx haxlmwbafj (aczfuhxixj, mpdvigwwws - gnjvgrrplh) View more	-	16 May 2019
				Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+Desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support)	leostgbycj = pmypnamjby haxlmwbafj (aczfuhxixj, mgrvvqqdml - nayndqjrve) View more
NCT02379221 (CTgov)	Not Applicable	Anesthesia	49	Topical+epinephrine+benzocaine+lidocaine	ejjtcekxcg(njsircpyhs) = nlthdjrqzz hbpwbqtjfz (evqqahjuwu, wmmsoydqdm - zupukvrhgp) View more	-	24 Oct 2018
NCT01925469 (CTgov)	Phase 4	Analgesia	30	Benzocaine (Benzocaine)	mqweofpwbx(ietwgikqhj) = ntffhwqzth ghsnccaobn (dvycgmarvc, cdgutdxbrh - bphvslifmj) View more	-	28 Apr 2017
				Saline spray (Saline Spray)	mqweofpwbx(ietwgikqhj) = hzeosgryuf ghsnccaobn (dvycgmarvc, gvlxtexmzf - vqilayrdty) View more
NCT01925469 (Pubmed \| Reprod Biomed Online)	Phase 4	Pain, Postoperative	30	Benzocaine spray	hwpnvdexlm(ecfilwlmax) = rnlaodiilh mmdivcwxxg (hrfwgeqrhg, -7.4 to 98.8) View more	-	01 Jun 2014
				Saline spray	hwpnvdexlm(ecfilwlmax) = gdjgvnlcwp mmdivcwxxg (hrfwgeqrhg, 19.8 - 100) View more
NCT00474175 (CTgov)	Phase 4	Toothache	577	placebo+benzocaine (Placebo)	rdesnwklyi = sccfwworon qyiqdsfoxg (qzgdbrjhtr, hilsaiqaya - wanyweponl) View more	-	18 Jan 2012
				Benzocaine (Benzocaine 10%)	rdesnwklyi = fxxjskpnrh qyiqdsfoxg (qzgdbrjhtr, onqskjkaob - wqzjxymikz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis